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doi:10.1Objective: Controversy exists regarding the optimal pumping method for left ventricular assist devices. The pur-
pose of this investigation was to test the hypothesis that pulsatile left ventricular assist synchronized to the cardiac
cycle provides superior left ventricular unloading and circulatory support compared with continuous-flow left
ventricular assist devices at the same level of ventricular assist device flow.
Methods: Seven male pigs were used to evaluate left ventricular assist device function using the TORVAD
synchronized pulsatile-flow pump (Windmill Cardiovascular Systems, Inc, Austin, Tex) compared with the
Bio-Medicus BPX-80 continuous-flow centrifugal pump (Medtronic, Inc, Minneapolis, Minn). Experiments
were carried out under general anesthesia, and animals were instrumented via a median sternotomy. Hemody-
namic measurements were obtained in the control state and with left ventricular assistance using the TORVAD
and BPX-80 individually. Left ventricular failure was induced with suture ligation of the mid-left anterior
descending coronary artery, and hemodynamic measurements were repeated.
Results: During left ventricular assist device support, mean aortic pressure and total cardiac output were higher
and left atrial pressure was lower with pulsatile compared with continuous flow at the same ventricular assist de-
vice flow rate. During ischemic left ventricular failure, pulsatile left ventricular support resulted in higher total
cardiac output (5.58  1.58 vs 5.12  1.19, P< .05), higher mean aortic pressure (67.8  14 vs 60.2  10,
P< .05), and lower left atrial pressure (11.5  3.5 vs 13.9  6.0, P< .05) compared with continuous flow at
the same left ventricular assist device flow rate.
Conclusion: Synchronized, pulsatile left ventricular assistance produces superior left ventricular unloading and
circulatory support compared with continuous-flow left ventricular assist at the same flow rates. (J Thorac
Cardiovasc Surg 2010;140:1181-8)Pulsatile left ventricular assist devices (LVADs) have inlet
and outlet valves with areas of stasis associated with embo-
lization and increased risk of stroke.1 They are also prone to
mechanical failure, typically do not synchronize with the
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SIn contrast, continuous-flow LVADs do not require valves
and their size is less bulky, but they also cannot synchronize
with the cardiac cycle and flow rates vary with preload and
after-load for a given pump speed.3,4 At maximum flow
rates, the aortic valve may not open, leading to potential
fusion of the aortic leaflets and thrombus formation in the
sinus of Valsalva, potentially increasing the risk of
cerebral embolization.5 In addition, aortic leaflet fusion
can induce aortic insufficiency and lead to the need for in-
creased VAD support, making weaning less likely.6 Throm-
bus formation has also been reported within the pumping
mechanism of continuous-flow devices.7
Continuous-flowdevices are frequently associatedwith ab-
sence of detectable pulses in patients with severe left ventric-
ular (LV) dysfunction, making determination of true arterial
blood pressure difficult.8 This makes it difficult to up-titrate
after-load reducing agents to ameliorate congestive heart fail-
ure symptoms and improve the chances for LV recovery.1,3
The TORVAD (Windmill Cardiovascular Systems, Inc,
Austin, Tex) LVAD is a valveless, pulsatile, rotary, dual-
piston, positive displacement pump with a controller,
power/sensor cable, and power supply. The pump performsdiovascular Surgery c Volume 140, Number 5 1181
Abbreviations and Acronyms
AoP ¼ aortic pressure
BTT ¼ bridge to transplant
ECG ¼ electrocardiogram
IV ¼ intravenous
LAD ¼ left anterior descending
LAP ¼ left atrial pressure
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
LVP ¼ left ventricular pressure
MAP ¼ mean arterial pressure
PVA ¼ pressure-volume area
SHE ¼ surplus hemodynamic energy
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Sblood aspiration and ejection by cyclically actuating a piston
around a toroidal pumping chamber via magnetic coupling
to a motor while maintaining a second piston in a stationary
position to occlude blood flow between the inlet and outlet
ports. As the first piston completes the cycle through the to-
rus, a second piston begins a cycle to maintain forward flow
while the first piston becomes stationary between the inlet
and outlet ports, which maintains unidirectional pulsatile
blood flow. No valves are required to produce forward blood
flow, there are no areas of stasis, and flow is primarily lam-
inar with very low shear. The current pump can eject up to
37.5 mL per stroke but can be programmed, using the inte-
grated control module, to eject fractions of the maximum
stroke volume. The pump actively aspirates blood from
the LV apex and delivers it to the ascending aorta in syn-
chrony with the native cardiac cycle via electrocardiographic
triggering. A schematic of the pump is depicted in Figure 1.
The pump can also be operated in an asynchronous, contin-
uous mode providing more than 8 liters of forward pulsatile
flow/min. A flow dynamic computer simulation suggested
that pulsatile flow synchronized to the cardiac cycle would
produce superior LV unloading and reduced LV work
compared with continuous flow at the same level of support.
There has never been a direct comparison between
a positive displacement, pulsatile flow, pump capable of
LV assistance synchronized with the cardiac cycle and a con-
tinuous-flow LVAD in terms of effectiveness of LV unload-
ing, optimal circulatory support, and reduced myocardial
work for a given level of circulatory support. The purpose
of this investigation was to test the hypothesis that pulsatile
LV assistance, synchronized with the cardiac cycle, provides
superior LV unloading and circulatory support when com-
pared with a continuous-flow LV assist device at a similar
level of LVAD flow.
MATERIALS AND METHODS
Because there are no hemodynamic circulatory loops capable of accu-
rately evaluating myocardial work and unloading comparing continuous1182 The Journal of Thoracic and Cardiovascular Surflow with synchronized pulsatile flow, an animal model was chosen. A total
of 16 male domestic farm raised pigs (Yorkshire/Poulin mixed) weighing
63 kg (53–73 kg) were used in this study. Five pigs were used to optimize
the aortic graft anastomosis and LV inflow cannula implantation location
and techniques. Four pigs were used to test the TORVAD pump function
and determine optimal timing of synchronization with the cardiac cycle
for LV unloading and circulatory support. To minimize the number of ani-
mals required for the study, both pumps were inserted in each study animal
with each animal serving as its own control. The remaining 7 pigs were used
for the final data set comparing the TORVAD with the BioMedicus model
BPX-80 centrifugal pump (Medtronic, Inc, Minneapolis, MN). Animals re-
ceived proper care in compliance with the AnimalWelfare Committee of the
University of Texas at Houston Medical School, and all experiments were
performed according to the Animal Welfare Committee’s guidelines.Surgical Procedure
Animals were sedated with an intramuscular injection of telazol 4 mg/kg
(Wyeth, Madison, NJ) and robinul (American Regent, Inc, Shirley, NY)
0.0009 mg/kg and endotracheally intubated. Anesthesia was initiated with
3% to 5% isoflurane, and animals were maintained under general anesthe-
sia with isoflurane 2% to 3% and mechanically ventilated with oxygen
while the body temperature was maintained at 38C with a heating pad.
A blood transfusion of up to 1 liter of donor pig blood (Lampire Biological
Laboratories, Inc, Pipersville, Pa) was given during the procedure as neces-
sary to replace surgical blood loss, and this was supplemented with normal
saline as necessary to ensure adequate volume status. All animals received
sodium heparin 150 U/kg intravenous (IV) bolus, and additional boluses, to
maintain an activated clotting time greater than 200 seconds. Before sternot-
omy, animals were given a loading dose of 5.0 mg/kg amiodarone (Ben
Venue Labs, Inc, Bedford, Ohio) and were maintained on a 1 mg/kg/h
drip to suppress arrhythmias. An IV lidocaine drip (1 mg/kg/h) was also
maintained throughout the procedure with additional boluses of lidocaine
(1–2 mg/kg) administered as needed for arrhythmias.
The internal carotid and jugular veins were exposed, and central venous
pressure was measured via the left internal jugular vein. A median sternot-
omy was performed. Left atrial pressure (LAP) was measured with a fluid-
filled pressure transducer (Becton Dickinson DTX Plus transducer, ref
682018, Becton Dickinson Infusion Therapy Systems, Sandy, Utah) via
a catheter placed in the left atrial appendage. Left ventricular pressure
(LVP) was measured with a Millar catheter (model SPR-524 3.5F
Mikro-tip Millar Instruments, Inc, Houston, Tex) placed near the LV
apex through a 4F sheath. Aortic pressure (AoP) was measured with
a Millar catheter placed in the ascending aorta. Aortic blood flow was mea-
sured with a 20-mm perivascular ultrasonic flow probe at the base of the
aorta (MA20PAX, Transonic Systems Inc, Ithaca, NY). LVAD pump
blood flow was measured with an ultrasonic flow probe attached to the
pump inflow cannula (ME11PXL Transonic Systems Inc, Ithaca, NY).
Ventricular volume was indirectly measured using 2 piezo-electric sonomi-
crometer crystals (Sonometrics Corp, London, Ontario, Canada, and Craig
J. Hartley, Baylor College of Medicine, Houston, Tex) sutured on the short
axis of the heart at the level of the papillary muscles. The surface electro-
cardiogram (ECG) was recorded. All measurements were acquired and re-
corded continuously with a 16-channel PONEMAH physiologic digital
data acquisition system (Data Sciences International, St Paul, Minn). Heart
failure was induced by ligation of the left anterior descending (LAD)
coronary artery after the first diagonal branch with a suture ligature after
baseline data were recorded.
The 12.7 mm inflow cannula was then inserted into the LV apex and se-
cured with horizontal mattress sutures of pledgeted 3-0 Prolene. A 10-mm
Dacron graft was then anastomosed to the brachiocephalic artery in an end-
to-side fashion with 7-0 Prolene while the brachiocephalic artery was
occluded proximally and distally. The TORVAD was primed with saline
and de-aired. The pump was then connected to the inflow and outflow can-
nulae via Y-connectors with careful detail given to exclude air bubbles.gery c November 2010
FIGURE 1. Schematic of the experimental preparation and instrumenta-
tion. LVV, Left ventricular volume crystals; LVP, left ventricular pressure
micromanometer;QVAD,VAD flow probe; LAP, left atrial pressure catheter;
QAo, aortic flow probe; AoP, aortic pressure micromanometer; CVP, central
venous pressure catheter.
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SA BioMedicus BPX 80 pump was then attached to the other end of the
Y-connectors in a similar fashion. Either LVAD could be isolated from
the circulation with tubing clamps allowing support of the circulation
with either LVAD independently. A schematic of the experimental setup
is depicted in Figure 1.
Hemodynamic Assessment
Once surgical implantation of the TORVAD and Bio-Medicus pumps
was completed, hemodynamics were assessed in 4 physiologic states: base-
line with and without LV assistance and failure after ligation of the mid-
LAD coronary artery with and without LV assistance. The failure modelThe Journal of Thoracic and Carwas produced using LAD ligation just distal to the first diagonal branch
to induce significant ischemia in the lower left ventricle, reducing LV con-
tractility and lowering cardiac output and mean AoP. The target LVAD flow
rate was 37.5 mL times the heart rate, which was the maximum stroke vol-
ume for the TORVAD when activated once during each cardiac cycle. The
TORVAD provided synchronous support using epicardial ECG triggering,
where a single ejection was performed with each heart beat timed in early
diastole. Thus, blood was actively aspirated from the LV apex and simulta-
neously delivered to the aorta providing an early-diastolic counterpulse
(Figure 2, C). This timing maintained the ejection of the native ventricle
through the aortic valve during systole (at reduced pre and after-load), which
allowed a significant portion of the cardiac output to be sensitive to the phys-
iologic flow regulators of ventricular preload and after-load.
At each physiologic state (baseline off and on support, followed by
LAD ischemic failure off and on support), each pump was allowed to
run for 5 minutes to allow for stabilization of hemodynamics before begin-
ning a 30-second data-collection period. After data had been collected with
1 pump, the tubing clamps were switched to redirect blood flow and sup-
port was established with the other pump. The data gathered included heart
rate, cardiac output (aortic plus LVAD flow), LVAD flow, AoP and aortic
flow, LVP, LAP, central venous pressure, epicardial ECG, and LV volume,
which was calculated from the epicardial diameter crystals. Data were
obtained in random order during either TORVAD or BioMedicus LVAD
support at the same blood flow rates. Instantaneous LV volume was calcu-
lated using a prolate semi-spheroid shell model of the left ventricle9 by the
formula
LVV ¼ p
6
ðb2hÞ2ða1:1hÞ
where the long axis (a) and wall thickness (h) were measured postmortem,
and the external short axis (b) was continuously obtained using the piezo-
electric crystal pair. Pressure-volume loops were then constructed using
high-fidelity LVP and the corresponding instantaneous LV volumes.
LVP-volume area (PVA) represents the total mechanical energy of con-
traction and correlates strongly with LV oxygen consumption.10 LV PVA is
the sum of the external mechanical work, which is the area in the LVP-
volume loop, and the mechanical potential energy, which is the area
contained by the pressure-volume loop, the end-diastolic pressure-volume
relationship curve, and the end-systolic pressure-volume relationship curve.
Surplus hemodynamic energy (SHE) is a measure of the extra energy
generated by cardiac or LVAD flow pulsation above the mean arterial pres-
sure (MAP)11 and quantifies pulsatility. SHE is obtained by subtracting
MAP from the energy equivalent pressure, which is calculated by dividing
the area beneath the hemodynamic power curve by the area beneath the
hemodynamic flow curve
SHE ¼
R
QPdt
R
Qdt
MAP
where Q is the total flow rate of the native aortic flow and VAD flow, and
P is the arterial pressure.
After the initial measurements in the control state, the LAD was ligated,
which resulted in LV ischemia and concomitant failure. After approxi-
mately 15 minutes of stable LV failure was achieved, hemodynamic mea-
surements were obtained on and off LVAD support with both pumps
sequentially, in random order for each animal. Each animal was then sacri-
ficed with IV supersaturated potassium chloride; the heart was excised from
the chest, and LV length and wall thickness measurements were determined
for use in the volume calculations as described above.RESULTS
Seven animals were instrumented, 1 animal died during
instrumentation, and the remaining 6 animals form the basisdiovascular Surgery c Volume 140, Number 5 1183
FIGURE 2. Hemodynamic recordings obtained from pig 14 during baseline (A), with LAD ligation and acute LV failure (B), with TORVAD (Windmill
Cardiovascular Systems, Inc, Austin, TX) support during failure (C), and with BioMedicus (Medtronic, Inc, Minneapolis, MN) support during failure
(D). AOP,Aortic pressure; LV, left ventricular; LVP, left ventricular pressure; LAP, left atrial pressure;QAO, transaortic valve flow; QVAD, ventricular assist
device output.
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with no LV assistance or with either TORVAD support or
BioMedicus support initially (randomly assigned). During
the data-collection periods, the heart rate remained at
approximately 90 beats/min. All animals were in sinus
rhythm and were not paced. As outlined in Table 1, at base-
line, the mean AoP was 73  13 mm Hg while the mean
LAP was 18  8 mm Hg and the cardiac output was
4.49  1.1 L/min. The average hematocrit was 27% 
2% at the beginning of the procedure pre-sternotomy and1184 The Journal of Thoracic and Cardiovascular Sur28% 4% during the period of data collection. All animals
were hemodynamically stable during the baseline and the
LV failure data-collection periods.
Hemodynamic Effects of Left Ventricular Assistance
in the Healthy Animal
The LVAD flow rate was constant with both devices to
ensure the measured results reflect the difference between
continuous versus synchronized pulsatile support indepen-
dently of changes in LVAD flow levels. With initiation ofgery c November 2010
TABLE 1. Hemodynamic measurements
Healthy Ligated
Baseline
TORVAD
(Windmill Cardiovascular
Systems, Inc, Austin, Tex)
BioMedicus (Medtronic,
Inc, Minneapolis, Minn) Baseline TORVAD BioMedicus
HR (bpm) 90  16 89  15 88  18 86  12 91  13 88  11
CO (L/m) 4.49  1.1 5.87  1.3* 5.42  1.2 3.54  1.25 5.58  1.58* 5.12  1.19
QVAD (L/m) 0.00  0.0 3.27  0.6 3.27  0.71 0.00  0.00 3.39  0.50 3.36  0.56
QAo 4.49  1.1 2.60  0.9* 2.15  0.84 3.54  1.25 2.19  1.36* 1.77  0.95
AoPmax (mm Hg) 96.0  9.0 100.5  18.8* 92.0  9.0 75.8  15.9 89.1  23.8* 74.9  14.7
AoPmin (mm Hg) 56.7  11.8 62.7  18.5 61.5  9.6 41.8  11.8 48.9  12.8 51.7  8.8
AoPavg (mm Hg) 73.1  12.5 82.0  17.3* 74.2  11.6 54.6  12.3 67.8  14.0* 60.2  10.0
LAPavg (mm Hg) 18.4  8.0 11.6  2.7* 13.2  3.7 18.9  8.0 11.5  3.4* 13.9  6.0
PVA (mL mm Hg) 6945  1972 5697  1382 6254  1901 4926  1114 4229  1179y 4560  1258
SHE (mm Hg) 14.3  3.2 7.4  6.7 5.9  1.3 13.5  2.3 7.6  6.4 3.8  2.2
HR, Heart rate; CO, cardiac output; QVAD, ventricular assist device flow; QAo, aortic valve flow; AoPmax,maximum aortic pressure; AoPmin,minimum aortic pressure; AoPavg,
average aortic pressure; LAPavg, average left atrial pressure; PVA, pressure-volume area; SHE, surplus hemodynamic energy. *P<.05 for TORVAD vs BioMedicus. yP<.10 for
TORVAD vs BioMedicus.
Letsou et al Evolving Technology/Basic Sciencepulsatile LV support with the TORVAD, the cardiac output
increased from 4.49  1.1 L/min to 5.87  1.3 L/min
(Table 1), which was higher than during BioMedicus
continuous-flow support (5.42  1.2 L/min, P < .05).
Both the maximum and the average AoP were elevated
with TORVAD support compared with both BioMedicus
support and at baseline. In addition, LAP was reduced dur-
ing TORVAD support and was lower than during BioMedi-
cus support (11.6  2.7 mm Hg vs 13.2  3.7 mm Hg,
P< .05).FIGURE 3. Cardiac output (A), aortic valve flow (B), mean LAP (C), andMAP
during LV failure after LAD occlusion and then with BioMedicus and TORVA
The Journal of Thoracic and CarHemodynamic Effects of Left Ventricular Assistance
During Acute Ischemic Failure
After ligation of the LAD just distal to the first diagonal
branch, the ventricle dilated in the anterolateral and apical
regions and the regionalwallmotionbecameakineticbyvisual
inspection. The animal’s hemodynamics were allowed to sta-
bilize, and although the heart rate did not change significantly,
the mean AoP decreased from 73  12.5 mm Hg to 54.6 
12.3mmHg (See Table 1 and Figure 3).With TORVAD sup-
port, the cardiac output increased from 3.54  1.25 L/min to(D) with LAD ligation during acute LV failure.Measurements were obtained
D support in random sequence.
diovascular Surgery c Volume 140, Number 5 1185
E
T
/B
S
FIGURE 4. Pressure-volume loops obtained from pig 14 during baseline,
with LAD ligation and acute LV failure, with BioMedicus support during
failure, and with TORVAD support during failure. LV, Left ventricular;
LVP, left ventricular pressure; LVV, left ventricular volume.
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support (P< .05). With TORVAD support, aortic flow was
reduced compared with baseline but remained higher than
aortic flow during BioMedicus support (2.19  1.36 L/min
vs 1.77 0.95 L/min, P<.05). MAP increased in TORVAD
supported animals to 67.8 14mmHgcomparedwith 60.2
10 mm Hg with BioMedicus support (P< .05). Similarly,
there was a reduction in LAP to 11.5  3.5 mm Hg in
TORVAD-supported animals compared with 13.9  6 mm
Hg in BioMedicus-supported animals (P< .05).
The differences between synchronized pulsatile and
continuous-flow support hemodynamics are illustrated by
Figure 2. During LAD ischemia in pig 14, a decrease in
mean AoP from 90 mm Hg to 62 mm Hg (Figure 2, A, B)
occurred similar to that observed in the other animals.
With TORVAD support, a distinct increase in aortic
diastolic pressure occurred compared with the BioMedicus
device (Figure 2, C, D). Once again, the LAP diminished
significantly in the TORVAD animals (11.8 mm Hg)
compared with the BioMedicus animals (14.4 mm Hg).Effect of Pulsatile Compared With Continuous-Flow
Left Ventricular Assist on Left Ventricular Work
The PVA serves as an index of LV work, which is de-
picted graphically with pig 14 data (Figure 4). With initia-
tion of LV failure, the LV generated less work. With
BioMedicus continuous-flow support, as shown in the small
dotted line in Figure 4, the PVA was reduced further;1186 The Journal of Thoracic and Cardiovascular Surhowever, with initiation of TORVAD support, the PVA
was reduced dramatically as depicted by the dotted line in
Figure 4. In the aggregate data (Table 1), during ischemic
heart failure, the LVP volume area was reduced from
4926  114 mL mm Hg to 4229  1179 mL mm Hg with
pulsatile LV support.
Impact of Pulsatile Compared with Continuous-Flow
Left Ventricular Assist on Arterial Pulsatility
SHE is an index of pulsatility of the AoP. With pulsatile
LV support, the SHEwas approximately twice that observed
during continuous-flow LV assist (7.6  6.4 mm Hg vs
3.8  2.2 mm Hg). The diastolic augmentation of AoP dur-
ing TORVAD counterpulse synchronized support (active
VAD flow from LV apex to aorta) was greater than
continuous-flow support with the BioMedicus pump
(Figure 2, C, D). During ischemic failure in pig 14, the
SHE increased from 12 mm Hg at baseline to 18 mm Hg
with synchronized pulsatile LV support compared with
2.4 mm Hg with continuous-flow support.
DISCUSSION
The Interagency Registry for Mechanically Assisted Cir-
culatory Support reported results in 483 patients implanted
with mechanical support devices primarily as bridge to
transplant (BTT).12 Over an 18-month period, in patients im-
planted with LVADs, the survival was similar between BTT
and destination therapy at approximately 60% to 70%.12
Although the earlier Randomized Evaluation of Mechanical
Assistance for the Treatment of Heart Failure Trial (RE-
MATCH) demonstrated improved outcomes in transplant-
ineligible patients treated with a pulsatile LVAD compared
with optimal medical therapy, the LVAD failure rate was
disappointing.13 In contrast, Long and colleagues,14 in
a study of 23 patients treated with a similar pulsatile-flow
LVAD (HeartMate model XVE, Thoratec Corp, Pleasanton,
CA) for destination therapy, reported a 77% 2-year survival
compared with 29% in the REMATCH trial. The HeartMate
II (Thoratec Corp, Pleasanton, Calif) investigators, in a BTT
population, reported that the continuous-flow HeartMate II
device resulted in an 18-month survival of 72%4 with a de-
vice failure rate lower than that observed in the REMATCH
trial, and the major causes of death included sepsis and
stroke4 rather than device failure.
The recently reported randomized trial comparing the
HeartMate XVE pulsatile device and the HeartMate II
continuous-flow device demonstrated that the continuous-
flow LVAD produced superior survival compared with the
pulsatile-flow device. This was due to improved HeartMate
II device longevity rather than the physiologic benefits of
continuous flow.15
No previously reported comparisons of pulsatile flow syn-
chronized to the cardiac cycle and continuous-flow LV sup-
port at the same level of LVADflow exist. In a recent study ofgery c November 2010
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with decreased renal function at device implant, there was
a distinct trend toward improved creatinine clearance in the
pulsatile-flow group.16 In a study comparing equal numbers
of patients on continuous-flow and pulsatile-flow devices for
12 months or longer, a significant improvement in LV re-
modeling and function was observed with pulsatile-flow
LVAD support.17 In the pulsatile-flow group, the LV end-
diastolic diameter decreased from 77 to 60 mm compared
with 69 mm in the continuous-flow group (P ¼ .012). Simi-
larly, the ejection fraction improved from 16% to 20% in the
pulsatile-flow group compared with no change in the
continuous-flow group (P ¼ .022).17 Only pulsatile support
has demonstrated reductions in ventricular mass.18
Travis and colleagues19 evaluated SHE in patients on
continuous-flow or pulsatile-flow LVAD support. At low
support levels, SHE was restored to within 2.5% normal
with pulsatile support but continuous-flow support dimin-
ished SHE. At high support levels, SHE increased 49%
with pulsatile flow, whereas continuous flow diminished
SHE by 97%. In addition, pulsatile support was associated
with normal vascular compliance, whereas continuous-
flow support resulted in stiffening of the vasculature.19
Blood at low shear rates has viscoelastic properties. With
increased pulsatility, the viscoelastic interaction of the eryth-
rocytes is reduced, which in turn reduces viscosity and there-
fore blood flow resistance in the tissue beds.20 As a result,
tissue oxygen delivery is enhanced in the gut,21 renal circu-
lation,22 and brain23 during circulatory bypass with pulsatile
flow compared with continuous flow.
In patients with severe aortic stenosis, small and large
bowel arteriovenous malformations are present, which
tend to bleed spontaneously. In addition, acquired Von Wil-
lebrand disease seems to develop in these patients.24 These
findings have been suggested as potential causative mecha-
nisms for the apparent increase in gastrointestinal bleeding
observed in patients with continuous axial flow LVADs
compared with little or no increased gastrointestinal
bleeding with pulsatile LVADs.24 We previously reported
near-fatal gastrointestinal bleeding associated with
continuous-flow LVADs, which resolved after cardiac trans-
plant and explantation of the VAD.25
Study Limitations
This acute experiment was performed in highly instru-
mented, anesthetized animals tested over relatively brief pe-
riods of time. Because of the coronary blood flow occurring
below the aortic flow probe, using aortic flow for the cardiac
output calculation might be slightly in error. It would also
have been desirable to have determined beneficial improve-
ments of end-organ perfusion with synchronized pulsatile
flow. In controlled experimental conditions, synchronization
with the cardiac cycle was feasible. However, in the clinical
environment, in the presence of dysrhythmias, synchroniza-The Journal of Thoracic and Cartion may be more challenging. Although these results are
compelling, further investigations in chronic animal im-
plants, and ultimately in humans, will be necessary to deter-
mine the true merit of a reliable pulsatile-flow LVAD that
can be synchronized to the cardiac cycle, particularly with
regard to potentially improved LV remodeling.CONCLUSIONS
Synchronized, pulsatile LV assistance is more physio-
logic and produces superior LV unloading compared with
continuous-flow LV assistance. We have demonstrated im-
proved pulsatility (SHE), reduced LV work, reduced LAP,
and improved cardiac output and AoP with pulsatile flow
synchronized with the cardiac cycle in early diastole com-
pared with continuous flow with the BioMedicus pump at
identical levels of LVAD flow. Programmable, pulsatile-
flow LVADs with controllable stroke volumes and pumping
characteristics may provide attractive devices, particularly
for bridge-to-recovery applications in patients with severe
heart failure.
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